Myelodysplastic Syndromes

Researchers Develop Improved Flow Cytometric Score for MDS Diagnosis

January 16th 2021, 3:30pm


A flow cytometric score developed in 2012, which uses 4 parameters to distinguish low-grade myelodysplastic syndromes (MDS) from nonclonal cytopenias, is simple and practical for screening patients with MDS, according to research published in the American Journal of Translational Research.

Analysis Reveals High Cost of Discontinued HMA Treatment for MDS

January 15th 2021, 8:07pm


New research underscores the substantial economic burden associated with early discontinuation of guideline-recommended hypomethylating agent (HMA) therapy among patients with refractory anemia with excess blasts, a diagnosis that substantially overlaps with higher-risk myelodysplastic syndrome (MDS).

PROs Used in Low-Risk MDS Found to Have Strong Face, Content Validity

January 9th 2021, 9:00pm


A recent study evaluated the content validity of patient-reported outcome instruments used in low-risk myelodysplastic syndrome (MDS).

Study Finds IWG 2006 Response Criteria Valid in Patients With Higher-Risk MDS

January 7th 2021, 5:15pm


Complete response to first-line therapy, as determined by the International Working Group 2006 response criteria, can be used as a surrogate end point for overall survival in higher-risk patients with myelodysplastic syndromes (MDS), according to a study published in Cancer Medicine.

Is a New Classification and Prognosis System Possible for Myelodysplastic Syndromes?

January 2nd 2021, 1:15pm


Integrating novel parameters into conventional risk stratification systems may better define patient subgroups in myelodysplastic syndromes (MDS), thus creating a more enhanced classification and prognostic scoring system for patients, say researchers.

Unanswered Questions Remain in Optimal Management of RBC Transfusions in MDS

January 1st 2021, 9:00pm


Questions remain about the optimal approach to transfusion management in myelodysplastic syndromes (MDS), particularly in the outpatient setting, leading a pair of researchers to review current evidence.

Heterogenous Nature of MDS Warrants Further Research, Review Finds

December 23rd 2020, 8:32pm


With a goal of moving toward more individualized therapeutic approaches, researchers said future advancements in understanding myelodysplastic syndrome (MDS) molecular mechanisms are needed to offer clinical decision making guidance.

Gene Expression Signatures Linked With Response to HMA Treatment in Patients With MDS

December 19th 2020, 2:00pm


Their work may help to further understanding of the molecular mechanisms of hypomethylating agents (HMAs) and offer a guide for determining which patients are likely to respond to such treatment.

For Patients With HMA-Resistant MDS, What Are Their Options?

December 18th 2020, 3:16pm


For patients who are resistant to hypomethylating agent (HMA) treatment, there are no formal treatment recommendations, but several options, spanning from novel HMAs to chemotherapy, have been or are currently being studied in the setting.

Study Finds Significant Survival Advantage for Patients With MDS Who Have HLA-Matched Donor for HCT

December 12th 2020, 3:47pm


The abstract, presented at the 2020 American Society of Hematology Annual Meeting and Exposition, found favorable overall survival and leukemia-free survival for these patients.